Shares of Sorrento Therapeutics (NASDAQ: SRNE) were up by 10.3% as of 2:02 p.m. EDT Thursday. Although the company hasn't released any news, the increase in new COVID-19 cases in many parts of the world may have investors thinking about the potential for Sorrento's COVI-STIX testing product.
Image source: Getty Images.
That product recently received emergency use authorization (EUA) in Mexico, where daily new diagnoses have risen by 50% in the past month. The company submitted a request to the FDA at the end of last year for authorization for the test's use in the U.S., and is also working toward getting it a green light in Europe.
For further details see:
Why Sorrento Therapeutics Is Climbing Today